
The antitrust regulator in Spain has accused Merck of working with other companies to hinder the entry of generic versions of a hormonal contraceptive, the latest effort by a European government to crack down on anti-competitive practices in the pharmaceutical industry.
In a statement issued the National Commission on Markets and Competition announced that it is pursuing sanctions against Merck Sharp & Dohme, its European affiliate, and MSD Human Health Holding, the European parent, for possibly delaying competitors from entering the market for a vaginal ring in Spain.
Full Content: Stat News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta’s $220 Million Fine in Nigeria Upheld by Competition Tribunal
Apr 27, 2025 by
CPI
DoorDash Proposes $3.6 Billion Acquisition of Deliveroo
Apr 27, 2025 by
CPI
US Judge Delays Approval of $2.8 Billion NCAA Settlement Over Athlete Rights
Apr 27, 2025 by
CPI
US Launches Criminal Antitrust Probe Into TP-Link’s Pricing Practices
Apr 27, 2025 by
CPI
CK Hutchison’s $22.8 Billion Port Sale to BlackRock Draws Chinese Scrutiny
Apr 27, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece